Published in Gastroenterology on October 20, 2009
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (2011) 1.94
Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Am J Gastroenterol (2015) 1.78
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med (2012) 1.71
Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer (2012) 1.32
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol (2011) 1.20
Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol (2014) 1.17
Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection. Int J Clin Oncol (2017) 1.14
The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol (2014) 1.12
Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics (2012) 1.10
Current management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2014) 1.10
Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2011) 1.07
Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging (2013) 1.00
Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol (2011) 1.00
Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection. Eur J Cancer (2012) 1.00
High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol (2013) 1.00
Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver (2013) 0.98
Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol (2012) 0.96
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol (2015) 0.96
Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies. World J Gastroenterol (2013) 0.94
Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection--results from a clinic-based longitudinal cohort. Eur J Cancer (2012) 0.94
Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J Hepatol (2016) 0.94
Current limitations and potential breakthroughs for the early diagnosis of hepatocellular carcinoma. Gut Liver (2011) 0.92
Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma. Carcinogenesis (2012) 0.91
Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol (2012) 0.91
Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients. Medicine (Baltimore) (2015) 0.90
Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol (2015) 0.90
Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma. Med Sci Monit (2013) 0.87
Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging? Curr Hepatol Rep (2015) 0.87
Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. J Proteome Res (2014) 0.86
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. Br J Cancer (2014) 0.86
Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World J Gastroenterol (2014) 0.85
Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol (2015) 0.85
Alpha-1-acid glycoprotein as potential biomarker for alpha-fetoprotein-low hepatocellular carcinoma. BMC Res Notes (2010) 0.84
Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. Hepat Med (2015) 0.84
Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol (2016) 0.83
Diagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma: A Meta-Analysis. Gastroenterol Res Pract (2014) 0.83
How grim is hepatocellular carcinoma? Ann Med Surg (Lond) (2014) 0.83
Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review). Oncol Rep (2016) 0.83
Using serum α-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff? PLoS One (2015) 0.83
Effects of statins on the risk of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2014) 0.82
HURP expression-assisted risk scores identify prognosis distinguishable subgroups in early stage liver cancer. PLoS One (2011) 0.82
Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma. J Med Life (2015) 0.81
Serum levels of soluble CD25 as a marker for hepatocellular carcinoma. Oncol Lett (2012) 0.80
Current status of alpha-fetoprotein testing. Gastroenterol Hepatol (N Y) (2011) 0.80
Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population. Hepat Mon (2015) 0.80
Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma. PLoS One (2016) 0.80
Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine (Baltimore) (2017) 0.79
Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PLoS One (2016) 0.79
Liver transplantation for hepatocellular carcinoma: past, present and future. Middle East J Dig Dis (2013) 0.79
Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma. J Histochem Cytochem (2013) 0.79
Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis. PLoS One (2015) 0.79
Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol (2015) 0.78
Alpha-Fetoprotein Detection of Hepatocellular Carcinoma Leads to a Standardized Analysis of Dynamic AFP to Improve Screening Based Detection. PLoS One (2016) 0.78
Evaluation of (131)I-anti-angiotensin II type 1 receptor monoclonal antibody as a reporter for hepatocellular carcinoma. PLoS One (2014) 0.78
Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase. PLoS One (2016) 0.77
Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm. Clin Gastroenterol Hepatol (2015) 0.77
Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet. World J Hepatol (2015) 0.77
Novel Lens culinaris agglutinin-reactive fraction of α-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α-fetoprotein concentrations. Int J Clin Oncol (2011) 0.77
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int (2017) 0.77
Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol (2016) 0.76
Development of Bifunctional Gadolinium-Labeled Superparamagnetic Nanoparticles (Gd-MnMEIO) for In Vivo MR Imaging of the Liver in an Animal Model. PLoS One (2016) 0.76
Early detection of hepatocellular carcinoma through surveillance using biomarkers. Gastroenterol Hepatol (N Y) (2014) 0.76
A non-smooth tumor margin on preoperative imaging predicts microvascular invasion of hepatocellular carcinoma. Surg Today (2016) 0.76
Role of surveillance in prevention of hepatocellular carcinoma. J Clin Exp Hepatol (2014) 0.76
Surveillance for hepatocellular carcinoma. J Clin Exp Hepatol (2014) 0.76
Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization. Int J Clin Oncol (2013) 0.76
Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma. J Hepatocell Carcinoma (2014) 0.75
Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep (2017) 0.75
Simple and robust diagnosis of early, small and AFP-negative primary hepatic carcinomas: an integrative approach of serum fluorescence and conventional blood tests. Oncotarget (2016) 0.75
Clinical utility of protein induced by vitamin K absence in patients with chronic hepatitis B virus infection. Biomed Rep (2012) 0.75
Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity. J Cancer (2016) 0.75
A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma. Medicine (Baltimore) (2016) 0.75
Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget (2016) 0.75
Hepatobiliary quiz-5 (2013). J Clin Exp Hepatol (2013) 0.75
Disease monitoring of hepatocellular carcinoma through metabolomics. World J Hepatol (2017) 0.75
Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B. PLoS One (2016) 0.75
Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. World J Hepatol (2015) 0.75
Imaging of hepatocellular carcinoma and image guided therapies - how we do it. Cancer Imaging (2017) 0.75
Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials (2014) 0.75
Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case-control study. BMC Gastroenterol (2015) 0.75
Surveillance for Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y) (2014) 0.75
Surveillance for Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y) (2016) 0.75
Noninvasive diagnosis of hepatocellular carcinoma. Clin Mol Hepatol (2012) 0.75
Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients. Sci Rep (2016) 0.75
Screening and Identification of ssDNA Aptamer for Human GP73. Biomed Res Int (2015) 0.75
Surveillance and Diagnosis of Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y) (2015) 0.75
Hepatocellular Carcinoma: Current Questions and Future Directions. Gastroenterol Hepatol (N Y) (2015) 0.75
Biomarkers for Hepatocellular Carcinoma. Biomark Cancer (2017) 0.75
IMPROVING EFFICIENCY IN BIOMARKER INCREMENTAL VALUE EVALUATION UNDER TWO-PHASE DESIGNS. Ann Appl Stat (2017) 0.75
Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal study. BMJ Open (2017) 0.75
Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV cirrhosis with Normal Alanine Transaminase. Cancer Epidemiol Biomarkers Prev (2017) 0.75
Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma. J Gastroenterol (2011) 0.75
Development and application of a fluorescence protein microarray for detecting serum alpha-fetoprotein in patients with hepatocellular carcinoma. J Int Med Res (2016) 0.75
PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine (Baltimore) (2017) 0.75
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol (2006) 20.28
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Hepatocellular carcinoma: recent trends in the United States. Gastroenterology (2004) 5.90
Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol (2004) 5.29
Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut (2001) 4.12
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A (1974) 3.24
Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med (1984) 2.76
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med (2003) 2.51
Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology (1994) 2.26
Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol (1994) 2.20
Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol (2001) 2.06
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology (2000) 1.95
Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res (2008) 1.91
Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology (2002) 1.72
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark (2007) 1.65
Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol (2000) 1.50
Screening tests for hepatocellular carcinoma. Clin Liver Dis (2005) 1.47
Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol (1999) 1.43
AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer (2008) 1.37
Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol (1987) 1.32
Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol (2006) 1.29
The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer (1998) 1.27
Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology (2002) 1.24
Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol (1999) 1.16
Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer (2000) 1.13
Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol (2006) 1.11
Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. Anticancer Res (1999) 1.09
Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II. Liver Int (2006) 0.98
Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology (1996) 0.98
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
The burden of selected digestive diseases in the United States. Gastroenterology (2002) 6.79
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology (2004) 5.83
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
AASLD position paper: the management of acute liver failure. Hepatology (2005) 5.09
Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr (2008) 5.01
Alcoholic hepatitis. N Engl J Med (2009) 4.98
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology (2003) 4.95
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A (2006) 4.84
The prevalence of celiac disease in the United States. Am J Gastroenterol (2012) 4.77
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Daily activity energy expenditure and mortality among older adults. JAMA (2006) 4.36
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Prevalence of estimated GFR reporting among US clinical laboratories. Am J Kidney Dis (2008) 3.55
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Perspective: a culture of respect, part 1: the nature and causes of disrespectful behavior by physicians. Acad Med (2012) 3.28
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology (2005) 3.12
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology (2014) 3.04
Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology (2008) 3.04
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Detection of acetaminophen protein adducts in children with acute liver failure of indeterminate cause. Pediatrics (2006) 2.96
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2004) 2.84
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metab (2011) 2.73
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology (2002) 2.68
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64